Mutant IDH1 is required for IDH1 mutated tumor cell growth.

Abstract

Frequent somatic hotspot mutations in isocitrate dehydrogenase 1 (IDH1) have been identified in gliomas, acute myeloid leukemias, chondrosarcomas, and other cancers, providing a likely avenue for targeted cancer therapy. However, whether mutant IDH1 protein is required for maintaining IDH1 mutated tumor cell growth remains unknown. Here, using a genetically engineered inducible system, we report that selective suppression of endogenous mutant IDH1 expression in HT1080, a fibrosarcoma cell line with a native IDH1(R132C) heterozygous mutation, significantly inhibits cell proliferation and decreases clonogenic potential. Our findings offer insights into changes that may contribute to the inhibition of cell proliferation and offer a strong preclinical rationale for utilizing mutant IDH1 as a valid therapeutic target.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.18632/oncotarget.577

Publication Info

Jin, Genglin, Christopher J Pirozzi, Lee H Chen, Giselle Y Lopez, Christopher G Duncan, Jie Feng, Ivan Spasojevic, Darell D Bigner, et al. (2012). Mutant IDH1 is required for IDH1 mutated tumor cell growth. Oncotarget, 3(8). pp. 774–782. 10.18632/oncotarget.577 Retrieved from https://hdl.handle.net/10161/17850.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.